Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Non-obstructive Hypertrophic Cardiomyopathy Clear all
Completed Phase 2 Interventional Results available

A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

NCT03442764
View directory record Official record
Conditions
Non-obstructive Hypertrophic Cardiomyopathy
Interventions
mavacamten, Placebo
Drug
Lead sponsor
MyoKardia, Inc.
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
32
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Jul 21, 2026, 6:11 PM EDT
Completed Phase 2 Interventional Results available

Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic Cardiomyopathy

NCT04219826
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy (HCM)
Interventions
CK-3773274 (5 - 15 mg), CK-3773274 (10 - 30 mg), Placebo for CK-3773274
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
18
States / cities
Los Angeles, California • San Francisco, California • Evanston, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Jul 21, 2026, 6:11 PM EDT
Completed Phase 3 Interventional

A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy

NCT05582395
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic
Interventions
Mavacamten, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Jul 21, 2026, 6:11 PM EDT
Completed No phase listed Observational

Long Term Effects of Enalapril and Losartan on Genetic Heart Disease

NCT00001534
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy, Left Ventricular Hypertrophy, Myocardial Ischemia
Interventions
Losartan
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 21, 2026, 6:11 PM EDT
Completed No phase listed Observational

The Role of Heart Stiff and Weak Atrium on Exercise Capacity in Patients With Hypertrophic Cardiomyopathy

NCT00074880
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 21, 2026, 6:11 PM EDT
Recruiting Early Phase 1 Interventional

Sodium Glucose Co-transporter (SGLT) Inhibitors in Nonobstructive Hypertrophic Cardiomyopathy

NCT06433050
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy Without Obstruction
Interventions
Sotagliflozin
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Jul 21, 2026, 6:11 PM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy

NCT04164732
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic
Interventions
LCZ696, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Stanford, California • Boston, Massachusetts • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Jul 21, 2026, 6:11 PM EDT
Completed Phase 2Phase 3 Interventional

A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM

NCT03723655
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy, Obstructive Hypertrophic Cardiomyopathy, Non-obstructive Hypertrophic Cardiomyopathy
Interventions
mavacamten
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
31
States / cities
Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Jul 21, 2026, 6:11 PM EDT
Recruiting Phase 2 Interventional

A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

NCT07023614
View directory record Official record
Conditions
Non-obstructive Hypertrophic Cardiomyopathy
Interventions
Ninerafaxstat 200mg MR, Placebo
Drug
Lead sponsor
Imbria Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
22
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jul 21, 2026, 6:11 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy

NCT06481891
View directory record Official record
Conditions
Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
33
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jul 21, 2026, 6:11 PM EDT
Recruiting Not applicable Interventional

Exercise Intolerance in Non-obstructive Hypertrophic Cardiomyopathy

NCT05818605
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Moderate Intensity Exercise Program
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Jul 21, 2026, 6:11 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial

NCT04826185
View directory record Official record
Conditions
Non-obstructive Hypertrophic Cardiomyopathy
Interventions
IMB-1018972, Placebo
Drug
Lead sponsor
Imbria Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
13
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Jul 21, 2026, 6:11 PM EDT
Completed Phase 2 Interventional Results available

Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy

NCT01150461
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
losartan, placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Jul 21, 2026, 6:11 PM EDT
Terminated No phase listed Observational

ENABLE-HCM - AI-ENabled Echocardiography With Ultrasound Beyond the Echo Lab for Better HCM Imaging and Expanded Access

NCT07155434
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy (HCM), Cardiac Imaging, Echocardiography, Mavacamten, Obstructive Cardiomyopathy, Hypertrophic
Interventions
Not listed
Lead sponsor
UltraSight
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jul 21, 2026, 6:11 PM EDT
Active, not recruiting Phase 3 Interventional

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM

NCT06081894
View directory record Official record
Conditions
Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Interventions
Aficamten, Placebo
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
60
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 46 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Jul 21, 2026, 6:11 PM EDT
Enrolling by invitation Phase 2Phase 3 Interventional

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

NCT04848506
View directory record Official record
Conditions
Symptomatic Hypertrophic Cardiomyopathy (HCM)
Interventions
Aficamten (5 - 20 mg)
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
52
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jul 21, 2026, 6:11 PM EDT
Terminated Not applicable Interventional

Effect of Personalized Accelerated Pacing in Symptomatic Patients With Non-Obstructive Hypertrophic Cardiomyopathy

NCT06775886
View directory record Official record
Conditions
Non-obstructive Hypertrophic Cardiomyopathy, Hypertrophic Cardiomyopathy
Interventions
myPACE+ algorithm
Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Jul 21, 2026, 6:11 PM EDT
Recruiting No phase listed Observational

Study of the Progression of Chronic Cardiovascular Conditions

NCT07420907
View directory record Official record
Conditions
Cardiovascular Disease (CVD), Heart Failure, Aortic Stenosis, Aortic Stenosis Disease, Hypertension, Hypertension (HTN), Hypertrophic Cardiomyopathy Patients, Hypertrophic Cardiomyopathy Without Obstruction, Hypertrophic Cardiomyopathy, Obstructive, Dilated Cardiomyopathy (DCM), Dilated Cardiomyopathy, Dilated Cardiomyopathy, Familial
Interventions
Not listed
Lead sponsor
Prolaio
Industry
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Jul 21, 2026, 6:11 PM EDT